Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539220 | 0.89 | MAPK1 (0.46) | MAPK1BACE1GPR119NR1H2RXRA | |
| SCHEMBL1395322 | 0.87 | POLB (0.47) | POLBKMT2AMAPK1 | |
| SCHEMBL17055316 | 0.87 | NR1H2 (0.45) | POLBKMT2AMAPK1NR1H2NR1H3 | |
| SCHEMBL1673531 | 0.87 | MEN1 (0.43) | KMT2AMAPK1LMNA | |
| SCHEMBL30872615 | 0.80 | NR1H2 (0.36) | POLBKMT2AMAPK1GPR119NR1H2 | |
| SCHEMBL1747847 | 0.80 | DDB1 (0.41) | POLBMAPK1BACE1GPR119DDB1 | |
| SCHEMBL11078567 | 0.77 | MAPK1 (0.44) | KMT2AMAPK1GPR119NR1H2RXRA | |
| SCHEMBL28459224 | 0.76 | GPR119 (0.50) | MAPK1BACE1GPR119 | |
| SCHEMBL17596208 | 0.76 | MAPK1 (0.45) | MAPK1BACE1GPR119NR1H2RXRA | |
| SCHEMBL15333427 | 0.76 | PDE1C (0.43) | POLBGPR119DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991226-B1 | INHIBITORS OF HISTONE DEACETYLASE | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| WO-2007100657-A2 | INHIBITORS OF HISTONE DEACETYLASE | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC6 | POLB 3180/4885KMT2A 60/4885MAPK1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.